Association of human XPA rs1800975 polymorphism and cancer susceptibility: an integrative analysis of 71 case–control studies

Table 6 FPRP values for the association between XPA rs1800975 and the risk of lung, skin, and colorectal cancers

Cancer type	Model	OR (95% CI)	P*	Prior probability level
Cancer type	Model	OR (95% CI)	P*	0.25	0.1	0.01	0.001	0.0001	0.00001
Lung cancer	Homozygotic model (GG vs AA)	0.87 (0.77–0.99)	0.035	0.094	0.238	0.774	0.972	0.997	1.000
	Heterozygotic model (AG vs. AA)	0.86 (0.76–0.97)	0.014	0.040	0.112	0.582	0.933	0.993	0.999
	Dominant model (AG + GG vs. AA)	0.87 (0.77–0.98)	0.022	0.062	0.164	0.684	0.956	0.995	1.000
Colorectal cancer	Allelic model (G vs. A)	1.20 (1.03–1.40)	0.020	0.058	0.156	0.670	0.953	0.995	1.000
	Homozygotic model (GG vs AA)	1.68 (1.15–2.44)	0.006	0.065	0.174	0.698	0.959	0.996	1.000
	Heterozygotic model (AG vs. AA)	1.46 (1.02–2.11)	0.044	0.191	0.415	0.887	0.987	0.999	1.000
	Dominant model (AG + GG vs. AA)	1.54 (1.08–2.20)	0.018	0.107	0.264	0.798	0.976	0.997	1.000
Skin cancer	Allelic model (G vs. A)	1.17 (1.09–1.25)	< 0.001	<0.001	<0.001	<0.001	<0.001	<0.001	0.247
	Carrier model (G vs. A)	1.12 (1.03–1.21)	0.004	0.012	0.035	0.286	0.802	0.976	0.998
	Homozygotic model (GG vs AA)	1.36 (1.17–1.57)	< 0.001	<0.001	<0.001	0.003	0.029	0.229	0.748
	Heterozygotic model (AG vs. AA)	1.18 (1.02–1.36)	0.022	0.063	0.167	0.688	0.957	0.996	1.000
	Dominant model (AG + GG vs. AA)	1.27 (1.10–1.45)	< 0.001	0.001	0.004	0.039	0.291	0.804	0.976
	Recessive model (GG vs. AA + AG)	1.20 (1.09–1.31)	< 0.001	< 0.001	< 0.001	0.005	0.044	0.316	0.822

OR odds ratio, CI 95% confidence interval, P* P value in Chi square test for genotype frequency distributions. FPRP value < 0.2 in italics

ISSN: 1475-2867